Thirty Years On, IVIG Clinical Research Keeps Rolling
Thirty years after its quiet introduction, unabated global research interest in IVIG reflects just how much remains unknown about its therapeutic potential.
The Plasma Industry: Investing Today to Ensure IG and Albumin Supply for Tomorrow
The plasma industry continues to plan and invest for the future to assure that immunoglobulin, albumin and other life-critical plasma products are on the shelf when they’re needed.
IVIG as Effective as Plasma Exchange in Treating Guillain Barré Syndrome
A meta-analysis showed IVIG was as effective as plasma exchange in reducing Guillain Barré syndrome disability scores, with no significant difference in adverse events.